Prespecified outcomes
ARDS
SECONDARY, ARDS
The primary endpoint was the change (Δ) in EVLWi between days 1 and 4. We chose this period to capture the effect of imatinib during the exudative phase of ARDS, characterized by vascular leak and alveolar flooding [The following key secondary outcomes were analyzed in hierarchical order: change in P